Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
The Oncologist|May 11, 2001
Docetaxel and herceptin: foundation for future strategiesM D Pegram
Clinical Breast Cancer|April 24, 2002
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerationsM D Pegram, C O'Callaghan
Seminars in Oncology|September 11, 1999
Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivityM D Pegram, D J Slamon
Breast Cancer Research and Treatment|March 5, 1999
HER-2/neu as a predictive marker of response to breast cancer therapyM D Pegram, G Pauletti, D J Slamon
American Journal of Clinical Pathology|August 1, 1987
Diagnosis of infective and inflammatory disorders by flow cytometric analysis of blood neutrophilsS A Bentley, M D Pegram, D W Ross
Seminars in Oncology|March 10, 2001
Trastuzumab and chemotherapeutics: drug interactions and synergiesM D Pegram, A Lopez, G Konecny, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 11, 1999
A model-based approach for assessing in vivo combination therapy interactionsA M Lopez, M D Pegram, D J Slamon, et al.
Oncogene|November 12, 1998
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugsR J Pietras, M D Pegram, R S Finn, et al.
Oncogene|July 31, 1997
The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cellsM D Pegram, R S Finn, K Arzoo, et al.
Oncogene|July 1, 1994
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cellsR J Pietras, B M Fendly, V R Chazin, et al.
Pageof 2